Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

Tarsus Pharmaceuticals logo
$78.68 -1.60 (-1.99%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$78.18 -0.50 (-0.63%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Tarsus Pharmaceuticals Stock (NASDAQ:TARS)

Advanced

Key Stats

Today's Range
$77.39
▼
$81.35
50-Day Range
$67.52
▼
$87.22
52-Week Range
$53.89
▼
$91.53
Volume
874,316 shs
Average Volume
968,559 shs
Market Capitalization
$3.88 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$104.57
Consensus Rating
Moderate Buy

Company Overview

Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for diseases with significant unmet medical needs, particularly in eye care. The company’s work includes therapies targeting Demodex mites, microscopic parasites associated with certain eye conditions.

Its lead product, XDEMVY (lotilaner ophthalmic solution), is an FDA-approved prescription treatment for Demodex blepharitis, an eyelid condition. Tarsus has also evaluated lotilaner-based candidates for other conditions, including ocular rosacea and Lyme disease prevention.

Founded in 2016 and based in Irvine, California, Tarsus is led by co-founder, president and chief executive officer Bobak Azamian. The company’s commercial activities have included bringing XDEMVY to the U.S. market.

AI Generated. May Contain Errors.

Tarsus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

TARS MarketRank™: 
3.380018674135 of 5 stars

Tarsus Pharmaceuticals scored higher than 68% of companies evaluated by MarketBeat, and ranked 282nd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Tarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Tarsus Pharmaceuticals has a consensus price target of $104.57, representing about 32.9% upside from its current price of $78.68.

  • Amount of Analyst Coverage

    Tarsus Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Tarsus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($15.64) to $0.72 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Tarsus Pharmaceuticals is -5.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Tarsus Pharmaceuticals is -5.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Tarsus Pharmaceuticals has a P/B Ratio of 37.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.62% of the float of Tarsus Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Tarsus Pharmaceuticals has a short interest ratio ("days to cover") of 6.94.
  • Change versus previous month

    Short interest in Tarsus Pharmaceuticals has recently increased by 5.85%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Tarsus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Tarsus Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Tarsus Pharmaceuticals has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Tarsus Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    5 people have searched for TARS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,004,227.00 in company stock.

  • Percentage Held by Insiders

    9.64% of the stock of Tarsus Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Tarsus Pharmaceuticals' insider trading history.
Receive TARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TARS Stock News Headlines

FY2026 Earnings Estimate for TARS Issued By HC Wainwright
Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
Tarsus to Participate in Upcoming Investor Conferences
See More Headlines

TARS Stock Analysis - Frequently Asked Questions

Tarsus Pharmaceuticals' stock was trading at $81.88 on January 1st, 2026. Since then, TARS shares have decreased by 3.9% and is now trading at $78.68.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) released its earnings results on Tuesday, November, 3rd. The company reported ($14.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.46) by $12.94. The firm had revenue of $194.57 million for the quarter, compared to analyst estimates of $187.83 million. Tarsus Pharmaceuticals had a negative net margin of 102.93% and a negative trailing twelve-month return on equity of 24.51%.
Read the conference call transcript
.

Tarsus Pharmaceuticals (TARS) raised $88 million in an IPO on Friday, October 16th 2020. The company issued 5,500,000 shares at $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

Tarsus Pharmaceuticals' top institutional investors include State Street Corp (2.24%), Goldman Sachs Group Inc. (1.66%), Assenagon Asset Management S.A. (1.40%) and Toronto Dominion Bank (0.33%). Insiders that own company stock include Bobak R Azamian, William J Phd Link, Seshadri Neervannan, Bryan Wahl, Jeffrey S Farrow, Aziz Mottiwala, Dianne C Whitfield, Andrew D Goldberg, Elizabeth Yeu Lin, Jose M Trevejo and Katherine Goodrich.
View institutional ownership trends
.

Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Tarsus Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Palantir Technologies (PLTR), Micron Technology (MU), CrowdStrike (CRWD), Salesforce (CRM) and NextEra Energy (NEE).

Company Calendar

Last Earnings
11/03/2026
Today
11/17/2026
38th Annual Healthcare Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:TARS
CIK
1819790
Fax
N/A
Employees
370
Year Founded
2017

Price Target and Rating

High Price Target
$116.00
Low Price Target
$97.00
Potential Upside/Downside
+32.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($15.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
109.28
P/E Growth
N/A
Net Income
-$66.42 million
Net Margins
-102.93%
Pretax Margin
-101.21%
Return on Equity
-24.51%
Return on Assets
-12.40%

Debt

Debt-to-Equity Ratio
0.70
Current Ratio
1.96
Quick Ratio
1.94

Sales & Book Value

Annual Sales
$451.36 million
Price / Sales
8.60
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.11 per share
Price / Book
37.29

Miscellaneous

Outstanding Shares
49,310,000
Free Float
44,553,000
Market Cap
$3.88 billion
Optionable
Optionable
Beta
0.34

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:TARS) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners